Physician
Lima Pathology Associates INC
Lima Pathology Associates INC was paid $1.28M by Medicaid between Jan 2018 and Nov 2024, across 124 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 52% of everything it billed.
33Billing provider infoLIMA PATHOLOGY ASSOCIATES INC
LIMA, OH 45801
LIMA, OH 45801
33aNPI1235115437assigned 12/20/2005
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$1.28M
24GClaims68,847
24DCodes billed124
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Ohio
Rank by total paid#10 of 90
Median peer was paid$23K
This provider vs. median57×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,998 | $589K | |
| 2019 | 9,660 | $195K | |
| 2020 | 2,512 | $101K | |
| 2021 | 3,702 | $114K | |
| 2022 | 3,568 | $118K | |
| 2023 | 3,738 | $107K | |
| 2024incomplete | 6,669 | $60K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 52% | 18,783 | 16,833 | $663K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.1% | 1,596 | 1,534 | $53K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.1% | 1,595 | 1,530 | $53K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.9% | 1,446 | 1,404 | $50K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.0% | 2,503 | 2,453 | $39K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.7% | 4,373 | 3,950 | $34K |
| 80053 | Comprehensive metabolic panel | 2.4% | 3,553 | 3,379 | $31K |
| 87902 | 2.4% | 151 | 148 | $31K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.0% | 1,096 | 1,083 | $26K |
| 80061 | Lipid panel | 1.7% | 1,796 | 1,777 | $22K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.7% | 752 | 739 | $22K |
| 80074 | 1.5% | 431 | 427 | $20K |
112 more codes
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.5% | 861 | $19K |
| 87522 | Neg quan hep c or qual rna | 1.2% | 349 | $15K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.1% | 486 | $14K |
| 88141 | <1% | 597 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,099 | $10K |
| 87480 | <1% | 474 | $9K | |
| 87510 | <1% | 474 | $9K | |
| 88307 | <1% | 148 | $9K | |
| 84439 | <1% | 1,008 | $9K | |
| 87660 | <1% | 476 | $7K | |
| 86803 | <1% | 515 | $7K | |
| 87340 | <1% | 693 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,123 | $6K |
| 88304 | <1% | 796 | $6K | |
| 85060 | <1% | 473 | $5K | |
| 82607 | <1% | 336 | $5K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 300 | $5K |
| 86592 | <1% | 1,108 | $5K | |
| 84403 | <1% | 233 | $5K | |
| 84702 | <1% | 305 | $5K | |
| 84153 | <1% | 234 | $4K | |
| 84481 | <1% | 247 | $4K | |
| 86762 | <1% | 270 | $4K | |
| 86480 | <1% | 57 | $4K | |
| 87070 | <1% | 561 | $3K | |
| 82746 | <1% | 162 | $2K | |
| 88342 | <1% | 98 | $2K | |
| 87186 | <1% | 322 | $2K | |
| 83655 | <1% | 181 | $2K | |
| 82728 | <1% | 153 | $2K | |
| 86376 | <1% | 141 | $2K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 50 | $2K |
| 87081 | <1% | 290 | $2K | |
| 83540 | <1% | 283 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 685 | $2K |
| 86038 | <1% | 128 | $2K | |
| 82570 | <1% | 310 | $2K | |
| 82043 | <1% | 264 | $2K | |
| 86696 | <1% | 79 | $2K | |
| 83550 | <1% | 171 | $1K | |
| 84436 | <1% | 207 | $1K | |
| 83525 | <1% | 122 | $1K | |
| 81001 | <1% | 625 | $1K | |
| 80050 | General health panel | <1% | 54 | $1K |
| 86800 | <1% | 71 | $1K | |
| 83516 | <1% | 39 | $1K | |
| 80076 | <1% | 199 | $981.50 | |
| 84480 | <1% | 71 | $977.53 | |
| 85651 | <1% | 327 | $974.73 | |
| 85027 | <1% | 353 | $944.30 | |
| 86850 | <1% | 301 | $878.44 | |
| 84703 | <1% | 211 | $839.08 | |
| 86695 | <1% | 61 | $800.63 | |
| 82248 | <1% | 289 | $769.60 | |
| 86900 | <1% | 329 | $696.08 | |
| 86901 | <1% | 328 | $693.00 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,040 | $665.86 |
| 82950 | <1% | 140 | $649.04 | |
| 84445 | <1% | 12 | $627.84 | |
| 87077 | <1% | 109 | $573.39 | |
| 86706 | <1% | 51 | $552.50 | |
| 87147 | <1% | 131 | $529.97 | |
| 83735 | <1% | 298 | $451.62 | |
| 87088 | <1% | 56 | $449.82 | |
| 84550 | <1% | 96 | $446.40 | |
| 86431 | <1% | 69 | $402.96 | |
| 82670 | <1% | 12 | $344.88 | |
| 81003 | <1% | 266 | $323.40 | |
| 85610 | <1% | 181 | $311.08 | |
| 88142 | <1% | 14 | $285.04 | |
| 84146 | <1% | 13 | $259.22 | |
| 85018 | <1% | 150 | $258.64 | |
| 84270 | <1% | 13 | $256.23 | |
| 86140 | <1% | 103 | $245.18 | |
| 83001 | <1% | 13 | $229.44 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $225.00 |
| 88112 | <1% | 22 | $220.72 | |
| 85014 | <1% | 89 | $200.08 | |
| 84460 | <1% | 40 | $179.85 | |
| 82784 | <1% | 15 | $172.26 | |
| 86780 | <1% | 32 | $163.44 | |
| 80348 | <1% | 12 | $127.32 | |
| 87205 | <1% | 93 | $114.40 | |
| 82977 | <1% | 14 | $103.74 | |
| 84450 | <1% | 25 | $95.94 | |
| 83690 | <1% | 126 | $79.64 | |
| 84520 | <1% | 25 | $77.33 | |
| 82947 | <1% | 15 | $52.52 | |
| 87653 | <1% | 37 | $29.24 | |
| 82077 | <1% | 79 | $27.20 | |
| 80143 | <1% | 38 | $14.68 | |
| 80179 | <1% | 39 | $14.68 | |
| 84484 | <1% | 146 | $4.50 | |
| 87040 | <1% | 62 | $2.40 | |
| 85379 | <1% | 19 | $2.40 | |
| 84145 | <1% | 44 | $1.80 | |
| 83880 | <1% | 57 | $1.50 | |
| 83605 | <1% | 95 | $0.90 | |
| 82330 | <1% | 29 | $0.90 | |
| 86880 | 0% | 13 | $0.00 | |
| 85730 | 0% | 62 | $0.00 | |
| 87807 | 0% | 12 | $0.00 | |
| 87625 | 0% | 41 | $0.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 17 | $0.00 |
| 82803 | 0% | 15 | $0.00 | |
| 82948 | 0% | 286 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 67 | $0.00 |
| 81025 | 0% | 32 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 108 | $0.00 |
| 87641 | 0% | 13 | $0.00 | |
| 85007 | 0% | 29 | $0.00 | |
| 87075 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYOUNT, MICHAEL (BUSINESS MANAGER)